Iovance Biotherapeutics, Inc. (IOVA)
Automate Your Wheel Strategy on IOVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOVA
- Rev/Share 0.722
- Book/Share 2.0881
- PB 1.2164
- Debt/Equity 0.0761
- CurrentRatio 3.2713
- ROIC -0.5225
- MktCap 919109160.0
- FreeCF/Share -0.9672
- PFCF -2.8408
- PE -2.1791
- Debt/Assets 0.0586
- DivYield 0
- ROE -0.5287
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IOVA | Goldman | Neutral | Sell | -- | $1 | July 15, 2025 |
| Downgrade | IOVA | UBS | Buy | Neutral | -- | $2 | May 16, 2025 |
| Downgrade | IOVA | Truist | Buy | Hold | -- | -- | May 12, 2025 |
| Downgrade | IOVA | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 9, 2025 |
News
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Over Securities Violations - Contact Levi & Korsinsky Today
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151284&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
Scott+Scott Attorneys at Law LLP Continues to Remind Investors There is a Securities Class Action Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. …
Read More
July 14, 2025 Deadline Approaching: Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151266&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.
Read More
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Journal of Clinical Oncology has published the final analysis from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel) in patients with advanced melanoma.
Read More
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151247&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
IOVA STOCK: Suffer Losses on Iovance Biotherapeutics, Inc.? BFA Law Notifies Investors of Imminent July 14 Securities Class Action Deadline (NASDAQ:IOVA)
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky to Join Class Action Before July 14, 2025
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151217&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.
Read More
IOVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").
Read More
Securities Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc. (IOVA) - Levi & Korsinsky Represents Shareholders
Published: June 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 1, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151196&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.
Read More
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
Published: June 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
Read More
Robbins LLP Reminds IOVA Stockholders That a Class Action Lawsuit was Filed Against Iovance Biotherapeutics, Inc. Alleging the Company Misled Investors Regarding its Business Prospects
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial-stage biopharmaceutical company which develops and commercializes cell therapies for the treatment of metastatic melanoma and other solid tumor cancers.
Read More
IOVA DEADLINE REMINDER: Iovance Biotherapeutics, Inc. Investors May Be Able to Recover Losses - Contact BFA Law by July 14 Class Action Deadline
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151035&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of July 14, 2025 Deadline
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150998&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.
Read More
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Published: May 30, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , May 30, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" …
Read More
July 14, 2025 Deadline Approaching: Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150748&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.
Read More
Investors in Iovance Biotherapeutics, Inc. Should Contact The Gross Law Firm Before July 14, 2025 to Discuss Your Rights – IOVA
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
Read More
Scott+Scott Attorneys at Law LLP Continues to Remind Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. …
Read More
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , May 29, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). IF YOU SUFFERED A LOSS ON YOUR IOVANCE INVESTMENTS, CLICK HERE BEFORE JULY 14, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. (IOVA) Investors of July 14, 2025 Deadline
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150739&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq.
Read More
Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically.
Read More
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky to Join Class Action Before July 14, 2025
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150670&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.
Read More
IOVA SECURITIES ALERT: Iovance Biotherapeutics, Inc. Investors Are Notified of The Pending Class Action; Contact BFA Law if You Lost Money
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Securities Fraud Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - Levi & Korsinsky Reminds Investors of July 14, 2025
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150588&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.
Read More
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150575&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
Read More
IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Published: May 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: May 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , May 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
Securities Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc. (IOVA) - Levi & Korsinsky Represents Shareholders
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150559&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.
Read More
About Iovance Biotherapeutics, Inc. (IOVA)
- IPO Date 2010-10-15
- Website https://www.iovance.com
- Industry Biotechnology
- CEO Frederick G. Vogt
- Employees 838